‘PSB losses wipe out $13 bn of infusions’

-
Situation likely to sustain in FY19: Fitch

from The Hindu - Business https://ift.tt/2LfOCMn

Comments

Post a Comment

Popular posts from this blog

DAILY INTRADAY TIPS FREE PRIVACY POLICY

-
This Privacy Policy is meant to help you understand what data we collect, why we collect it, and what we do with it. This is important; we hope you will take time to read it carefully. 1. Personal Information We do not collect any personal information from our app users. If you send us a query or feedback via email, your email address will be visible to us and when a reply is necessary we will use your email address to contact you directly. 2. Disclosure of Personal Information We do not disclose your personal information to any third party. 3. Permissions Required The app requires different Permissions depending on their functionality: 1) The "READ_EXTERNAL_STORAGE" permission is used for read the saved files by this apps asset. 2) The "WRITE_EXTERNAL_STORAGE" permission is used for the reader to save information caches; you can also manage your files saved in local storage with the reader directly by this permission. 3) And Internet, Wifi_state, Networ...
Read more

Moody's downgrades PNB on impact of Nirav Modi fraud

-
Image
MUMBAI: International rating agency Moody's today said it has downgraded state-run Punjab National Bank's (PNB) rating to Ba1/NP from Baa3/P-3, due to impact on the lender's profitability following Nirav Modi-fraud case. It kept the ratings outlook as stable but also downgraded the bank's baseline credit assessment (BCA) and Adjusted BCA to b1 from ba3. "The downgrade of the bank's BCA and ratings reflects the negative impact of the discovery of a number of fraudulent transactions on the bank's standalone profile, particularly its capital position," the rating agency said in a report here today. The downgrade also reflects the weak internal controls and processes of the bank, given that the fraudulent transactions were undetected for a number of years. In February, the bank announced that it had discovered some fraudulent and unauthorised transactions amounting to Rs 11,390, billion ($1.7 billion). Based on the bank's subsequent announcements,...
Read more

Aurobindo net dips 1% on ARV sales

-
Aurobindo Pharma Ltd. reported fourth-quarter net profit slid less than 1% to ₹528.76 crore from ₹532.22 crore a year earlier.Revenue from operations Aurobindo Pharma Ltd. reported fourth-quarter net profit slid less than 1% to ₹528.76 crore from ₹532.22 crore a year earlier. Revenue from operations grew 11.2% to ₹4,049.1 crore. A 43.3% decline in anti-retroviral product portfolio sales to ₹148.6 crore impacted performance. The company, however, registered sales growth in the formulations business in the U.S., Europe and Growth Markets. Total formulations, including ARV, grew 12.8% to ₹3,248.6 crore during the quarter. The company reported a 4.8% increase in the API sales to ₹799.6 crore. For the full fiscal, net profit grew by over 5% to ₹2,422.92 crore (₹2,301.2 crore), while the total revenue from operations increased by 9.3% at ₹16,499.8 crore (₹15,089.9 crore). Managing director N. Govindarajan said the company has reported a healthy growth in revenues and profitability in ...
Read more